



Curriculum Vitae

Personal information **Maria Driessens**

Work experience

1. Employer: Disphar International
 - Start date: 052006
 - End date: 072012
 - Position: Regulatory Affairs Associate
 - Activities: Manage Marketing Authorisation Applications, variations, renewals and PSUR submissions, risk minimisation, compliance
 - Country: Netherlands
2. Employer: VSOP
 - Start date: 032013
 - End date:
 - Position: Policy advisor research
 - Activities: Working with patient organizations in building registries, communication to achieve awareness, policy on orphan drugs, health economics, information via websites www.zichtopzeldzaam.nl, www.zeldzameaandoening.nl & www.patientenregisters.org
 - Country: Netherlands
3. Employer: Hubrecht Laboratory, Netherlands Cancer Institute
 - Start date: 081996
 - End date: 072012
 - Position: Various post_doctoral research positions
 - Activities: Research, grant applications, publications, supervision of students
 - Country: Netherlands

Education and training

1. Subject: The Netherlands Cancer Institute
 - Start date: 071990
 - End date: 071996
 - Qualification: PhD
 - Organisation: Thesis Lymphoma metastasis: Adhesion molecules and signalling processes involved in adhesion and invasion. Cell biology, molecular biology, protein purification and characterisation.
 - Country: Netherlands
2. Subject: Utrecht University
 - Start date: 091984
 - End date: 071990
 - Qualification: MSc Medical Biology, Faculty of Medicine
 - Organisation: major Immunology, minors Endocrinology and developmental biology
 - Country: Netherlands

Additional information

Publications

Report of the European Medicines Agency Conference on RNA-Based Medicines. Ehmann F, et al. doi: 10.1089/nat.2023.0021

Ethical aspects of hemophilia gene therapy: a qualitative interview study with stakeholders. Baas L, et al. DOI: 10.1016/j.rpth.2023.102237

Desmopressin in nonsevere hemophilia A: patient perspectives on use and efficacy. Romano L, et al. DOI: 10.1016/j.rpth.2023.100281

Personal health records: a promising tool?. Brands MR, et al. Ned Tijdschr Geneeskd. 2023 Mar 16;167:D6908.

Pain while injecting emicizumab predominant in children, a report of Dutch patient experiences. Kruis IC & Driessens MHE, DOI: 10.1111/hae.14757

Socioeconomic participation of persons with hemophilia: Results from the sixth hemophilia in the Netherlands study. Van Balen EC, et al. DOI: 10.1002/rth2.12741

Validation of the pedHALshort and HALshort in Dutch children and adults with haemophilia. Kuijlaars IAR. et al. DOI: 10.1111/hae.14628

Major differences in clinical presentation, diagnosis and management of men and women with autosomal inherited bleeding disorders. Atiq, F., Saes, J.L., Punt, M.C., van Galen, K.P.M., Schutgens, R.E.G., Meijer, K., Cnossen, M.H., Laros_Van Gorkom, B.A.P., Peters, M., Nieuwenhuizen, L., Kruip, M.J.H.A., de Meris, J., van der Bom, J.G., van der Meer, F.J.M., Fijnvandraat, K., Kruis, I.C., van Heerde, W.L., Eikenboom, H.C.J., Leebeek, F.W.G., Schols, S.E.M., 2021. EClinicalMedicine 32, 100726. <https://doi.org/10.1016/j.eclinm.2021.100726>

Validation of PROMIS Profile - 29 in adults with hemophilia in the Netherlands. Balen, E.C., Haverman, L., Hassan, S., Taal, E.M., Smit, C., Driessens, M.H., Beckers, E.A.M., Coppens, M., Eikenboom, J., Hooimeijer, H.L., Leebeek, F.W.G., Vulpen, L.F.D., Schols, S.E.M., Terwee, C.B., Rosendaal, F.R., Bom, J.G., Gouw, S.C., 2021. J. Thromb. Haemost. 19, 2687–2701. <https://doi.org/10.1111/jth.15454>

Von Willebrand Factor Multimer Densitometric Analysis: Validation of the Clinical Accuracy and Clinical Implications in Von Willebrand Disease. Boender, J., Atiq, F., Cnossen, M.H., van der Bom, J.G., Fijnvandraat, K., de Meris, J., de Maat, M.P.M., van Galen, K.P.M., Laros_van Gorkom, B.A.P., Meijer, K., Eikenboom, J., Leebeek, F.W.G., 2021. HemaSphere 5, e542. <https://doi.org/10.1097/HS9.0000000000000542>

Health and treatment outcomes of patients with hemophilia in the Netherlands, 1972–2019. Hassan, S., Balen, E.C., Smit, C., Mauser - Bunschoten, E.P., Vulpen, L.F.D., Eikenboom, J., Beckers, E.A.M., Hooimeijer, L., Ypma, P.F., Nieuwenhuizen, L., Coppens, M., Schols, S.E.M., Leebeek, F.W.G., Driessens, M.H., Rosendaal,

F.R., Bom, J.G., Gouw, S.C., 2021a. *J. Thromb. Haemost.* 19, 2394–2406. <https://doi.org/10.1111/jth.15424> Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001–2018. Hassan, S., Monahan, R.C., Mauser - Bunschoten, E.P., Vulpen, L.F.D., Eikenboom, J., Beckers, E.A.M., Hooimeijer, L., Ypma, P.F., Nieuwenhuizen, L., Coppens, M., Schols, S.E.M., Leebeek, F.W.G., Smit, C., Driessens, M.H., Cessie, S., Balen, E.C., Rosendaal, F.R., Bom, J.G., Gouw, S.C., 2021b. *J. Thromb. Haemost.* 19, 645–653. <https://doi.org/10.1111/jth.15182> A tailored intervention for illness acceptance improves adherence and quality of life in adults with haemophilia using prophylaxis. Hoefnagels, J.W., Fischer, K., Bos, R.A.T., Driessens, M.H.E., Schrijvers, L.H., 2021. *Haemophilia* 27. <https://doi.org/10.1111/hae.14320> Social participation is reduced in type 3 Von Willebrand disease patients and in patients with a severe bleeding phenotype. Kempers, E.K., Kwawegen, C.B., Meris, J., Schols, S.E.M., Galen, K.P.M., Meijer, K., Cnossen, M.H., Bom, J.G., Fijnvandraat, K., Eikenboom, J., Atiq, F., Leebeek, F.W.G., for the WiN study group, 2021. *Haemophilia* hae.14475. <https://doi.org/10.1111/hae.14475> Validation of a perioperative population factor VIII pharmacokinetic model with a large cohort of pediatric hemophilia patients. Preijers, T., Liesner, R., Hazendonk, H.C.A.M., Chowdary, P., Driessens, M.H.E., Hart, D.P., Laros - van Gorkom, B.A.P., Meer, F.J.M., Meijer, K., Fijnvandraat, K., Leebeek, F.W.G., Mathôt, R.A.A., Cnossen, M.H., for the “OPTI - CLOT” study group, 2021. *Br J Clin Pharmacol* 87, 4408–4420. <https://doi.org/10.1111/bcp.14864> Maternal and neonatal bleeding complications in relation to peripartum management in hemophilia carriers: A systematic review. Punt, M.C., Waning, M.L., Mauser - Bunschoten, E.P., Kruij, M.J.H.A., Eikenboom, J., Nieuwenhuizen, L., Makelburg, A.B.U., Driessens, M.H.E., Duvekot, J.J., Peters, M., Middeldorp, J.M., Bloemenkamp, K.W.M., Schutgens, R.E.G., Lely, A.T., van Galen, K.P.M., 2021. *Blood Reviews* 49, 100826. <https://doi.org/10.1016/j.blre.2021.100826> A qualitative study on the experiences of haemophilia carriers before, during and after pregnancy. Punt, Marieke C., Teela, L., Fischer, K., Bloemenkamp, K.W.M., Lely, A.T., Driessens, M.H.E., Pekel, L., Haverman, L., Galen, K.P.M., 2021. *Haemophilia* 27. <https://doi.org/10.1111/hae.14396> Similar sports participation as the general population in Dutch persons with haemophilia; results from a nationwide study. Versloot, O., Balen, E.C., Hassan, S., Schols, S.E.M., Leebeek, F.W.G., Eikenboom, J., Coppens, M., Vulpen, L.F.D., Smit, C., Driessens, M.H.E., Net, J., Gouw, S.C., Fischer, K., the Haemophilia in the Netherlands 6 steering committee, 2021. *Haemophilia* 27, 876–885. <https://doi.org/10.1111/hae.14366> Informed consent for neonatal trials: practical points to consider and a check list. Aurich B, Vermeulen E, Elie V, Driessens MHE, Kubiak C, Bonifazi D, Jacqz_Aigrain E. *BMJ Paediatr Open*. 2020 4(1) The experiences and attitudes of hemophilia carriers around pregnancy: A qualitative systematic review. Punt MC, Aalders TH, Bloemenkamp KWM, Driessens MHE, Fischer K, Schrijvers MH, van Galen KPM. *J Thromb Haemost.* 2020 18(7):1626_1636. Patient Perspectives on Novel Treatments in Haemophilia: A Qualitative Study. van Balen EC, Wesselo ML, Baker BL, Westerman MJ, Coppens M, Smit C, Driessens MHE, Leebeek FWG, van der Bom JG, Gouw SC. *Patient.* 2020 13(2):201_210. Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001_2018. Hassan S, Monahan RC, Mauser_Bunschoten EP, van Vulpen LFD, Eikenboom J, Beckers EAM, Hooimeijer L, Ypma PF, Nieuwenhuizen L, Coppens M, Schols SEM, Leebeek FWG, Smit C, Driessens MH, le Cessie S, van Balen EC, Rosendaal FR, van der Bom JG, Gouw SC. *J Thromb Haemost.* 2020 A feasibility study on two tailored interventions to improve adherence in adults with haemophilia. Hoefnagels JW, Fischer K, Bos RAT, Driessens MHE, Meijer SLA, Schutgens REG, Schrijvers LH. *Pilot Feasibility Stud.* 2020;6(1):189. Desmopressin treatment combined with clotting factor VIII concentrates in patients with non-severe haemophilia A: protocol for a multicentre single-armed trial, the DAVID study. Schütte LM, Cnossen MH, van Hest RM, Driessens MHE, Fijnvandraat K, Polinder S, Beckers EAM, Coppens M, Eikenboom J, Laros_van Gorkom BAP, Meijer K, Nieuwenhuizen L, Mauser_Bunschoten EP, Leebeek FWG, Mathôt RAA, Kruij MJA. *BMJ Open.* 2019 One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate P® /Humate P® treatment in von Willebrand disease patients. de Jager NCB, Bukkems LH, Heijdra JM, Hazendonk CHCAM, Fijnvandraat K, Meijer K, Eikenboom J, Laros_van Gorkom BAP, Leebeek FWG, Cnossen MH, Mathôt RAA; OPTI_CLOT group. *J Thromb Haemost.* 2019 Patient Perspectives on Novel Treatments in Haemophilia: A Qualitative Study. van Balen EC, Wesselo ML, Baker BL, Westerman MJ, Coppens M, Smit C, Driessens MHE, Leebeek FWG, van der Bom JG, Gouw SC. *Patient.* 2019 s40271_019_00395_6 Maternal and neonatal bleeding complications in relation to peripartum management in women with Von Willebrand disease: A systematic review. Punt MC, Waning ML, Mauser_Bunschoten EP, Kruij MJA, Eikenboom J, Nieuwenhuizen L, Makelburg ABU, Driessens MHE, Duvekot JJ, Peters M, Middeldorp JM, Bloemenkamp KWM, Schutgens REG, Lely AT, Van Galen KPM. *Blood Rev.* 2019:100633. Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery. Preijers T, Hazendonk HCAM, Liesner R, Chowdary P, Driessens MHE, Hart D, Keeling D, Laros_van Gorkom BAP, van der Meer FJM, Meijer K, Fijnvandraat K, Leebeek FWG, Collins PW, Cnossen MH, Mathôt RAA; OPTI - CLOT study group. *J Thromb Haemost.* 2018 Nov;16(11):2196_2207. Perioperative replacement therapy in haemophilia B: An appeal to “B” more precise. Hazendonk HCAM, Preijers T, Liesner R, Chowdary P, Hart D, Keeling D, Driessens MHE, Laros_van Gorkom BAP, van der Meer FJM, Meijer K, Fijnvandraat K, Leebeek FWG, Mathôt RAA, Collins PW, Cnossen MH. *Haemophilia.* 2018 Jul;24(4):611_618. A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients. Hazendonk H, Fijnvandraat K, Lock J, Driessens M, van der Meer F, Meijer K, Kruij M, Gorkom BL, Peters M, de Wildt S, Leebeek F, Cnossen M, Mathôt R; “OPTI_CLOT” study group. *Haematologica.* 2016 101(10):1159_1169. Perioperative treatment of hemophilia A patients: blood group O patients are at risk of bleeding complications. Hazendonk HC, Lock J, Mathôt RA, Meijer K, Peters M, Laros_van Gorkom BA, van der Meer FJ, Driessens MH, Leebeek FW, Fijnvandraat K, Cnossen MH. *J Thromb Haemost.* 2016 14(3):468_78. Lock J, de Bekker_Grob EW, Urhan G, Peters M, Meijer K, Brons P, van der Meer FJ, Driessens MH, Collins PW, Fijnvandraat K, Leebeek FW, Cnossen MH, “OPTI_CLOT” study group; Facilitating the implementation of pharmacokinetic_guided dosing of prophylaxis in haemophilia care by discrete choice experiment. *Haemophilia.* 2016, 22(1):e1_e10. Hazendonk HC, van Moort I, Fijnvandraat K, Kruij MJ, Laros_van Gorkom BA, van der Meer FJ, Meijer K, Peters M, Schutgens RE, Zwaan CM, Driessens MH, Polinder S, Leebeek FW, Mathôt RA, Cnossen MH. The “OPTI_CLOT” trial. A randomised controlled trial on periOperative Pharmacokinetic_guided dosing of CLOTTing factor concentrate in haemophilia A. *Thromb Haemost.* 2015;114(3):639_44. van Laake LW, van den Driesche S, Post S, Feijen A, Jansen MA, Driessens MH, Mager JJ, Snijder RJ, Westermann CJ, Doevendans PA, van Echteld CJ, ten Dijke P, Arthur HM, Goumans MJ, Lebrin F, Mummery CL Endoglin has a crucial role in blood cell-mediated vascular repair. *Circulation.* (2006) 114 :2288. Carvalho RLS, Driessens MHE and CL Mummery. Vasculogenesis and angiogenesis: Lessons from Genetics in Mice. *Comm. Theoret Biol.* (2002) 7:381_416 Driessens MHE , Olivo C, Nagata K, Inagaki M and JG Collard. B plexins activate Rho through PDZ_RhoGEF. *FEBS Lett.* (2002) 529:168_72. Krugmann S, Jordens I, Gevaert K, Driessens MHE, Vandekerckhove J, Hall A. Cdc42 induces filopodia by promoting the formation of an IRSp53:Mena complex. *Curr Biol.* (2001) 11:1645_55. Driessens MHE , Hu H, Nobes CD, Self A, Jordens I, Goodman CS and A Hall. Plexin B semaphorin receptors interact directly with active Rac and regulate the actin cytoskeleton by activating Rho. *Curr. Biol.* (2001) 11:339_44. Johansson A, Driessens MHE and P Aspenström. The mammalian homologue of the caenorhabditis elegans polarity protein PAR_6 is a binding partner for the Rho GTPases Cdc42 and Rac1. *J. Cell Sci.* (2000) 113:3267_3275. Soede RDM, Driessens MHE, Ruuls_Van Stalle L, Van Hulten PEM, Brink A and E Roos. LFA_1 to LFA_1 signals involve ξ associated protein_70 (ZAP_70) tyrosine kinase: relevance for invasion and migration of a T cell hybridoma. *J.Immunol.* (1999) 163: 4253_61. Driessens MHE , Van Run PEM, Van Rijthoven EAM and E Roos. Activation of G_proteins with AIF_4 induces LFA_1 mediated adhesion of T_cell hybridoma cells to ICAM_1 by signal pathways that differ from phorbol ester-induced manganese induced adhesion. *Exp. Cell Res.* (1997) 231:242_50. Driessens MHE , Van Run PEM, La Rivière G and E Roos. Inhibition and stimulation of LFA_1 and Mac_1 functions by antibodies against murine CD18. Evidence that the LFA_1-binding sites for ICAM_1, _2, and _3 are distinct. *J. Leukoc. Biol.* (1996) 60:758_65. Driessens MHE , Van Rijthoven EAM, La Rivière G and E Roos. Expression of pertussis toxin adenosine diphosphatase transferase in a T_cell hybridoma reduces metastatic capacity. *Blood* (1996) 88:3116_23. Driessens MHE , Stroeken PJM, Rodriguez Erena NF, Van der Valk MA, Van Rijthoven EAM and E Roos. Targeted disruption of CD44 in MDAY_D2 lymphosarcoma cells has no effect on subcutaneous growth or metastatic capacity. *J. Cell Biol.* (1995) 131:1849_55. Driessens MHE , Van Rijthoven EAM, Kemperman H and E Roos. Adhesion of

lymphoma cells to fibronectin: differential use of $\alpha 4\beta 1$ and $\alpha 5\beta 1$ integrins and stimulation by the 9EG7 mAb against the murine $\alpha 1$ integrin subunit. Cell Adhes. Commun. (1995) 4:327_36. Kemperman H, Driessens MHE , La Rivière G, Meijne AML and E Roos. Adhesion mechanisms in liver metastasis formation. Cancer Surv . (1995) 24:67_79. Meijne AML, Driessens MHE , La Rivière G, Casey DM, Feltkamp CA and E Roos. LFA_1 redistribution during T_cell hybridoma invasion of hepatocyte cultures and manganese_induced adhesion to ICAM_1. J. Cell Sci. (1994) 107: 2557_66. La Rivière G, Klein Gebbinck JW, Driessens MHE and E Roos.

Projects

European Projects Conect4Children (IMI), PedCrim, Symphonyconsortium.nl for rare bleeding disorders, Hemophilia in the Netherlands _ 6, HIN_6 , steering committee Pregnancy and Inherited Bleeding disorders, the PRIDES study, steering committee.

Memberships

EMA CAT patient representative (07_2013 _ 06_2019). World Federation of Hemophilia (2011) ZonMw, PSIDER Pluripotent Stem cell research, committee Rational Use Medicines (06_2015 _ 06_2020) HemoNED Foundation, Board member, www.hemoned.nl (10_2016 _ EAHAD 2019 _ 2020

Other Relevant Information

I am a patient representative